Alignment Healthcare, Inc. (NASDAQ:ALHC) Receives $24.30 Consensus PT from Analysts

Alignment Healthcare, Inc. (NASDAQ:ALHC) has been assigned an average rating of “Moderate Buy” from the ten analysts that are presently covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $24.30.

A number of analysts recently issued reports on the company. Wall Street Zen raised Alignment Healthcare from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. UBS Group reissued a “neutral” rating on shares of Alignment Healthcare in a research report on Wednesday, July 8th. Raymond James Financial set a $22.00 price target on Alignment Healthcare in a research note on Thursday, May 7th. Barclays dropped their price objective on Alignment Healthcare from $19.00 to $16.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 26th. Finally, Zacks Research downgraded Alignment Healthcare from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th.

Alignment Healthcare News Summary

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Q2 earnings and revenue beat expectations: Alignment reported adjusted earnings of $0.17 per share, above the $0.13 consensus estimate and up from $0.07 a year earlier. Revenue reached $1.34 billion, exceeding the $1.31 billion estimate and rising 31.6% year over year. Alignment Healthcare Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Improved profitability: Second-quarter net income more than doubled to $36.6 million as medical-care costs for members in its Medicare Advantage plans eased. The company said it surpassed the high end of guidance across key metrics, supporting investor confidence in its cost-management efforts. Alignment Healthcare Turns Profit as Insurer Gets Handle on Costs
• Neutral Sentiment: Revenue outlook was broadly in line: Alignment guided to approximately $1.3 billion in third-quarter revenue and $5.2 billion for full-year 2026, matching consensus estimates. The provided guidance did not include usable EPS figures, limiting the market’s ability to assess the earnings outlook.
• Negative Sentiment: Investor investigations add risk: Kaplan Fox, Lowey Dannenberg and Pomerantz announced investigations into possible federal securities-law violations involving Alignment Healthcare. These announcements do not establish wrongdoing, but they may increase legal, financial and reputational uncertainty and weigh on the stock. Lowey Dannenberg Alignment Healthcare Investigation

Insider Buying and Selling at Alignment Healthcare

In other Alignment Healthcare news, CEO John E. Kao sold 298,000 shares of the company’s stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $20.36, for a total transaction of $6,067,280.00. Following the sale, the chief executive officer directly owned 1,386,766 shares of the company’s stock, valued at approximately $28,234,555.76. This represents a 17.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Dawn Christine Maroney sold 30,000 shares of the stock in a transaction on Friday, May 15th. The shares were sold at an average price of $16.09, for a total transaction of $482,700.00. Following the completion of the sale, the president owned 998,813 shares of the company’s stock, valued at approximately $16,070,901.17. This represents a 2.92% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,039,951 shares of company stock valued at $19,976,967 in the last 90 days. Company insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On Alignment Healthcare

A number of institutional investors and hedge funds have recently modified their holdings of ALHC. Wellington Management Group LLP grew its holdings in Alignment Healthcare by 167.3% during the third quarter. Wellington Management Group LLP now owns 11,089,727 shares of the company’s stock worth $193,516,000 after purchasing an additional 6,940,277 shares during the period. Bank of New York Mellon Corp increased its position in Alignment Healthcare by 232.5% during the first quarter. Bank of New York Mellon Corp now owns 3,313,110 shares of the company’s stock worth $58,377,000 after buying an additional 2,316,777 shares during the last quarter. Invesco Ltd. raised its stake in Alignment Healthcare by 122.3% in the second quarter. Invesco Ltd. now owns 4,170,529 shares of the company’s stock valued at $58,387,000 after buying an additional 2,294,739 shares during the period. Capital World Investors bought a new stake in Alignment Healthcare in the fourth quarter valued at approximately $44,203,000. Finally, Loomis Sayles & Co. L P acquired a new stake in shares of Alignment Healthcare in the fourth quarter valued at approximately $44,162,000. 86.19% of the stock is owned by institutional investors.

Alignment Healthcare Stock Up 1.7%

Alignment Healthcare stock opened at $18.61 on Tuesday. The company has a current ratio of 1.58, a quick ratio of 1.58 and a debt-to-equity ratio of 1.56. Alignment Healthcare has a 1-year low of $12.91 and a 1-year high of $25.12. The company has a fifty day simple moving average of $19.73 and a 200 day simple moving average of $19.80. The company has a market cap of $3.85 billion, a P/E ratio of 206.78, a price-to-earnings-growth ratio of 2.47 and a beta of 1.05.

Alignment Healthcare (NASDAQ:ALHC) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.13 by $0.04. Alignment Healthcare had a net margin of 0.47% and a return on equity of 11.50%. The firm had revenue of $1.34 billion for the quarter, compared to analysts’ expectations of $1.31 billion. During the same period in the previous year, the firm posted $0.07 EPS. The company’s revenue for the quarter was up 31.6% on a year-over-year basis. Research analysts anticipate that Alignment Healthcare will post 0.2 earnings per share for the current fiscal year.

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.